SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

MSI NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

INDEX SEARCH RESULT

2021.09.19 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer - HTML (w)

2021.09.17 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS) - HTML (w)

2021.09.17 | 13:10 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer - HTML (w)

2021.09.17 | 00:05 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021 - HTML (w)

2021.09.15 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche opens access to pathology imaging tools to improve patient care - HTML (w)

2021.09.09 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases - HTML (w)

2021.09.08 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine - HTML (w)

2021.09.07 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers - HTML (w)

2021.09.01 | 01:01 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ?(inclisiran) - HTML (w)

2021.08.30 | 07:15 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

NOVARTIS

puce Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO - HTML (w)

2021.08.27 | 17:45 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer - HTML (w)

2021.08.24 | 18:00 | Permanent Information Releases / General Company News

German version HTML (w) Mail

SIKA

puce SIKA ÜBERNIMMT KOMPLETTANBIETER VON WATERPROOFING-LÖSUNGEN IN CHINA - HTML (w)

2021.08.24 | 18:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

SIKA

puce SIKA ACQUIRES FULL-RANGE WATERPROOFING EXPERT IN CHINA - HTML (w)

2021.08.24 | 07:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma - HTML (w)

2021.08.23 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

CLARIANT

puce Clariant acquires remaining 70% in Brazilian Personal Care specialty company Beraca to seize full control - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1000